News
2020
-
-
Kobe University and Sysmex Conducted Clinical Evaluation of the ELISPOT Method: A New Test for COVID-19 using blood
- Report on T cell Immunity to SARS-CoV-2 in the Japanese Population - (PDF：561KB)
-
-
Sysmex Obtains Marketing Approval for the HISCL™ IFN-λ3 Assay Kit, a Test Kit to Assist in Determining Exacerbation Risk in Novel Coronavirus (SARS-CoV-2)-Positive Patients (PDF：172KB)
-
-
Sysmex Launches Surgical Robot Unit, hinotori™ Surgical Robot System (PDF：154KB)
-
-
Sysmex Obtains Manufacturing and Marketing Approval for a SARS-CoV-2 Antigen Detection Reagent
- Detecting SARS-CoV-2 Antigens Using Fully Automated Immunoassay Systems HISCL™-5000 / HISCL™-800 - (PDF：170KB)
-
-
Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
- The Content Presented at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference - (PDF：182KB)
-
-
Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2021 (PDF：438KB)
-
-
Sysmex Announces Financial Forecast for the Fiscal Year Ending March 31, 2021 (PDF：83KB)
-
-
Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
- Presenting the Most Recent Data at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference - (PDF：120KB)
-
-
Sysmex Applies for Manufacturing and Marketing Approval for a SARS-CoV-2 Antigen Detection Reagent
- Detecting SARS-CoV-2 Antigens Using Fully Automated Immunoassay Systems HISCL™-5000 / HISCL™-800 - (PDF：130KB)
-
-
Medicaroid receives Japanese regulatory approval for the “hinotori™ Surgical Robot System”, the first made-in-Japan robotic assisted surgery system
-
-
Collaboration of Medicaroid, Kawasaki Heavy Industries and Sysmex for the business of the "hinotori™ Surgical Robot System", a robotic assisted surgery system (PDF：389KB)
-
-
Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2021 (PDF：433KB)
-
-
Sysmex Announces Dividend Forecast for the Fiscal Year Ending March 31, 2021 (PDF：102KB)
-
-
Insurance Coverage Received for Liquid Biopsy RAS Gene Mutation Testing for Colorectal Cancer Using High-Sensitivity Digital PCR (PDF：186KB)
-
-
Sysmex Launches OncoGuide™ NET Expert Panel Support System in Cancer Genome Profiling
- Supporting the Establishment of a System for Efficient Cancer Genomic Medicine - (PDF：151KB)
-
-
Sysmex Launches Lab Assay Service for Research on Cytokines Related to the Novel Coronavirus (SARS-CoV-2)
- Aiming to Monitor the Risk of Increasing Severity and Treatment Effects in Clinical Applications - (PDF：326KB)
-
-
Sysmex Launches New Products in the Hemostasis Field: Automated Blood Coagulation Analyzers CN-6500/CN-3500
- Using Chemiluminescence Enzyme Immunoassay to Enhance Testing Workflow Efficiency - (PDF：188KB)
-
-
The National Cancer Center, the National Center for Global Health and Medicine, and Sysmex Corporation Evaluate a SARS-CoV-2 Antibody Test with Support from the Japan Health Research Promotion Bureau
- Performance Report on an Antibody Detection Reagent Using Clinical Specimens - (PDF：314KB)
-
-
The City of Kobe, Kobe City Medical Center General Hospital, and Sysmex Corporation Working to Launch from Kobe the Clinical Implementation of a New Test for the Novel Coronavirus
- Collaborating with Medical Institutions of the Foundation for Biomedical Research and Innovation at Kobe to Strengthen Measures Allowing Early-Stage Diagnosis and Prediction of Severity - (PDF：171KB)
-
-
Sysmex to Launch Novel Coronavirus (SARS-CoV-2) Antibody Lab Assay Service and Antibody Measurement Reagents (for Research)
- Using the HISCL™-5000/HISCL™-800 Fully Automated Immunoassay Systems to Realize SARS-CoV-2 Antibody Detection - (PDF：150KB)
-
-
Sysmex Obtains First Marketing Approval in Japan for the Automated Hematology Analyzer XN-31 as a Class III Specially Controlled Medical Device to Diagnose Malaria
- For Use as a Measure against Imported Infectious Diseases in Japan and Accelerating its Introduction to the Asian and African Markets - (PDF：178KB)
-
-
Our Views and Policy regarding Investment Unit Reduction (PDF：94KB)
-
-
Sysmex Launches Flow Cytometer XF-1600 in North America
- Contribute to higher efficiency and standardization of the laboratory workflow for FCM testing - (PDF：180KB)
-
-
The Use of Saliva in PCR Tests for the Novel Coronavirus
- Expanding the Scope of Sample Types - (PDF：168KB)
-
-
Sysmex and OPTiM Jointly Establish New Company to Plan, Develop and Operate Medical AI and IoT Open Platforms and Digital Transformation Solutions (PDF：153KB)
-
-
Information about Litigation against Sysmex Corporation and its Subsidiary (PDF：105KB)
-
-
Sysmex Donates ¥30 Million to Kobe City Support Fund for Medical Professionals to Support COVID-19 Countermeasures (PDF：107KB)
-
-
The City of Kobe, Sysmex and SRL Configure and Begin Operating a PCR Testing System for COVID-19 within the Kobe Biomedical Innovation Cluster (PDF：105KB)
-
-
Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2020 (PDF：234KB)
-
-
Sysmex Announces Changes from Financial Forecasts and Year-End Dividend for the Fiscal Year Ended March 31, 2020 (PDF：46KB)
-
-
Announcement of Executive Change (PDF：137KB)
-
-
Advanced Medical Care Approval for Cancer Gene Panel Testing at the Time of Initial Treatment
- Prospective Study to Assess the Feasibility and Clinical Utility of Comprehensive Genomic Profiling at the Time of Initial Treatment of Patients with Solid Tumors - (PDF：122KB)
-
-
Sysmex Obtains First Marketing Approval in Japan for the Novel Coronavirus Nucleic Acid Detection Kits (RT-PCR Method)
- Aiming for early introduction of test kits for in vitro diagnostic medical devices in medical institutions - (PDF：183KB)
-
-
Announcement of Organizational and Personnel Changes (PDF：376KB)
-
-
Sysmex to Introduce New Globally Consistent Job-Based HR Management System with the Aim of Realizing Sustainable Growth
-
-
Sysmex and the Kobe City Eye Hospital Sign a Comprehensive Collaboration Agreement
-Reinforcing Collaboration toward the Realization of Genomic Medicine in the Area of Ophthalmic Disorders- (PDF：120KB)
-
-
Sysmex Presents Academic Report Related to the Clinical Utility of RAS Gene Mutation Testing for Colorectal Cancer Using Liquid Biopsy
Details of Report on Clinical Utility of OncoBEAM™ RAS CRC Kit presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2020 (ASCO-GI 2020) (PDF：130KB)
-
-
Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2020 (PDF：506KB)
-
-
Sysmex and RIKEN Innovation Sign a Comprehensive Collaborative Agreement
-
-
Sysmex Invests in Astrego Diagnostics with a View to Developing New Urinalysis Solutions for the Primary Care Business
-
-
Sysmex Receives Regulatory Approval in China of an in Vitro Diagnostic Reagent to Help Diagnose Breast Cancer Lymph Node Metastasis Using the OSNA™ Method
-Aiming to Introduce a System to Test for Breast Cancer Lymph Node Metastasis into the Chinese Market-
-
-
Sysmex Launches Gene Testing Kit for Blood Cancer (ipsogen JAK2 DX Reagent)
First Insurance Coverage in Japan for JAK2V617F Gene Mutation Testing for Myeloproliferative Neoplasms
